NCT06285916 - A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Depression, PostpartumPostpartum DepressionPost-partum DepressionPostnatal DepressionPost-Natal Depression

Interventions

DRUG

NORA520 Dose 1

Oral NORA520 tablets Dose 1 for 3 days

DRUG

NORA520 Dose 2

Oral NORA520 tablets Dose 2 for 3 days

DRUG

Placebo

Oral Placebo tablets for 3 days

Trial Locations (18)

11004

Zucker Hillside Hospital, Glen Oaks

28112

Monroe Biomedical Research, Monroe

30030

CenExel Clinical Research, Decatur

30331

Cenexel Clinical Research, Atlanta

31405

CenExel Clinical Research, Savannah

32807

Combined Research, Orlando

33014

Meridian International Research, Inc., Miami Gardens

33060

Clinical Research Center of Florida, Pompano Beach

33145

MedOne Clinical Research, Miami

33607

GCP Research, St. Petersburg

60616

Insight Hospital and Medical Center Chicago, Chicago

72712

Pillar Clinical Research, Bentonville

75080

Pillar Clinical Researc, Richardson

77573

Maximos Ob/Gyn, League City

90504

Cenexel Clinical Research, Torrance

91304

Alliance Research Institute, Canoga Park

91403

Cenexel Clinical Research, Sherman Oaks

92805

Advanced Research Center, Anaheim